Skip to main content
Explore URMC
menu
URMC / Research / Clinical Trials / Study Details

IMMY19114 /CC-220-MM-001/ Brea Lipe

Research Question:
What is the maximum tolerated dose, safety, and efficacy of CC-220 as a single therapy and in combination with other treatments in subjects with Multiple Myeloma?

Basic Study Information

Purpose:
This is a multicenter, multi-country, open-label, Phase 1b/2a dose-escalation study consisting of two parts: dose escalation (Part 1) for CC-220 monotherapy, CC-220 in combination with DEX, CC-220 in combination with DEX and DARA, CC-220 in combination with DEX and BTZ and CC-220 in combination with DEX and CFZ; and the expansion of the RP2D (Part 2) for CC-220 in combination with DEX for Relapsed Refractory Multiple Myeloma and CC-220 in combination with DEX and BTZ for Newly Diagnosed Multiple Myeloma.

Location: University of Rochester Medical Center
Study Reference #: IMMY19114

Lead Researcher (Principal Investigator)

Lead Researcher:  Brea Lipe

Study Contact Information

Study Coordinator: Amber Johnson
Email: amber_johnson@urmc.rochester.edu

Additional Study Details

Return to Search